NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most sign ...
Diagnostic thresholds of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) for heart failure with preserved ejection fraction (HFpEF) in ambulatory patients with chronic dyspnearequire ...
Elevated levels of N-terminal pro–B-type natriuretic peptide (NT-proBNP), a key biomarker for diagnosing heart failure, show a nearly fourfold increased risk for atrial fibrillation (AF) in at-risk ...
Clinical Trials Arena on MSN
CVRx’s stock up as heart failure device to be trialled in expanded patient group
The device gained approval in the US in 2019 and received CE marking for use in the EU in 2014.
Please provide your email address to receive an email when new articles are posted on . Select adults with ischemic heart failure with reduced ejection fraction may derive benefit from an ...
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...
PAH therapies improved hemodynamic parameters and reduced NT-proBNP levels in PH-ILD patients, indicating potential benefits. Precision medicine could help identify PH-ILD patients who may benefit ...
Zomedica launches two canine assays for TRUFORMA, including NT-proBNP for heart disease and progesterone for breeding. The assays provide reference lab-level accuracy in-clinic, enhancing diagnostics ...
In patients with heart failure (HF) caused by Chagas disease, sacubitril/valsartan was superior to enalapril for the composite primary endpoint, predominantly driven by a significant reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results